those pond #$%$ animals
everything stunk around that FDA hold/ Had he not pushed it though bfr the hold it would have been suicide afterwards........ this way he went into the collaborative talks holding a fistful of money and hadstretched the MF trials out till Jansssen picked it up.................not great for shareholders but great for the goose
shorting this after Dec would have been the smart move.$5Dec .+ $2.50 shorting after Dec would have been $7.50 same as 1 year EST
This going to be a $100 stock, at least when Janssen figures out how it works. There is that better?
sad thing was the 85% drop in 2014 on the FDA hold. This recent downdraft was a no news take down in a higher risk stock.
janssen could announce it wasn't going ahead and SP looks like it's heading to $.79 on an express train 3 days of -8% drops during the last month.
you knew this earlier and ever said anything till after we hit $2.55 Covered your shorts yet Joko?.
fisherman have you noticed the 45% drop in SP over the last five weeks? If you were an investor you'd be freaking out, not rehashing articles from several weeks ago. That is the reason why I don't think that you are an investor, but rather an employee of GERN.
HMMMMMMMMMMMMM at half the value of Proteolix, GERN;s current market cap at $452 could be bought out at 2x current value by Janssen making it closer to $5.72. Almost dead on with Chippy's option's price of $5.80
"Geron's experimental blood cancer drug has blockbuster potential
Geron's story is long, complicated, and full of disappointment for investors. However, the tiny biotech's investing thesis radically changed when CEO John Scarlett restructured the company to focus exclusively on the development of the telomerase-inhibitor imetelstat as a treatment for blood-based disorders such as myelofibrosis, myelodysplastic syndrome, and essential thrombocythemia.
"Scarlett is known in the biotech industry for striking favorable buyout deals for his former companies. In 2009, for instance, Scarlett helped engineer an $850 million buyout of Proteolix while carfilzomib (Kyprolis) was still in midstage testing. Since then, Kyprolis has gone on to become an important growth driver at Amgen.
After inking a development deal for imetelstat with Johnson & Johnson's (NYSE:JNJ) subsidiary Janssen Biotech and dramatically slashing the company's workforce by 46% in 2015, Scarlett seems intent on selling Geron as well. Adding fuel to the fire, J&J itself sports a lengthy track record of acquiring promising experimental cancer treatments from clinical-stage companies.
Looking ahead, Geron's fate appears to depend on imet studies for MDS |& MF. If the drug doesn't get derailed in these studies by its known safety and tolerability issues, Geron could either sell itself or use the money from imet's milestone payments from J&J to reconstitute its clinical pipeline.
The downside risk -- and it's significant -- is that imet flames out in one or more of its ongoing clinical studies. After all, Geron does seem to be structured for a quick sale if imet hits pay dirt, meaning that the biotech has little to fall back on if the things don't go as planned. "
I was right on MEIP provide you never held through to results which I stated afterwards. They were delayed by over a month. Out of context Joko at it again. As to the short that was a rhetorical comment to you Joko as to what you just did after pumping the stock the previous day and watching it drop 15% the next. You are a low life pond #$%$ worm. Curious why spend so much time on my posts? Cat got your tongue What's management hiding?
we discussed at length on this site weeks ago. Seems its all old info regarding the science and nothing pertaining the politics going on with the SP which to me is far more important as an investor. If charity is what your looking for donate to the cancer research program of your choice. This is about the drug and financing it to market to make financial returns. To package it any other way is stupid. Even Irish trader does not invest in GERN yet she certainly is opinionated about slipping time frames. 2 years worth on MF alone.